Prostate Cancer Daily

June 18, 2026

Videos

Peer-to-Peer Clinical Conversations

Radiopharmaceuticals in Prostate Cancer Part 3B: Radiation Safety, Patient Selection, and Clinical Gaps - Tanya Dorff, Neal Shore & Dustin Boothe

Tanya Dorff

In the second part of the Radiopharmaceuticals in Prostate Cancer: Patient Selection and Treatment Sequencing discussion, Phillip Koo continues the conversation with Dustin Boothe, Neal Shore, and Tanya Dorff on practical and clinical considerations in radiopharmaceutical therapy for prostate cancer.

Study on Metastatic Hormone-Sensitive Prostate Cancer Survival Trends - Neeraj Agarwal

Neeraj Agarwal

Neeraj Agarwal discusses a Flatiron database analysis examining treatment intensification in metastatic hormone-sensitive prostate cancer.

Beyond the Abstracts

Risk-Adapted Follow-up after Negative MRI-Targeted Biopsy in PI-RADS 3-5 Lesions: A Clinical Cohort Study with Diagnostic Stewardship Modeling - Beyond the Abstract

Radical Prostatectomy Outcomes in Patients with PI-RADS 5 Lesions and Favorable Prostate Cancer - Beyond the Abstract

Conference Coverage

SNMMI 2026: Does Early 177Lu-PSMA-617 SPECT/CT Improve Prognostic Assessment Beyond Baseline PSMA PET in mCRPC?

ASCO 2026: A Randomized Phase Ib/II Study of Enzaltuamide with and Without Ribociclib in Patients with mCRPC That Retains RB Expression: RiboX Study

ASCO 2026: Image-Only and Multimodal AI Digital Pathology Biomarkers to Demonstrate Risk Stratification Across Standard Prostate Cancer Management Strategies

AUA 2026: Real-World Outcomes of Triplet Intensification in High-Volume Metastatic Hormone-Sensitive Prostate Cancer in Japanese Patients from the Prospective YUSHIMA Registry: Propensity-Weighted and Bayesian RMST Analysis

AUA 2026: Advanced Prostate Cancer - Doublet Versus Triplet: Who Needs Additional Treatment Intensification for mHSPC?

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Single-port robotic radical prostatectomy: early results from a UK centre.

Integrative Oncology for Prostate Cancer: A Narrative Review.

3D Genome Architecture and Epigenetic Regulation of Lineage Identity in Advanced Prostate Cancer.

Targeted Prostate Health Checks for prostate cancer in men at high risk: a feasibility pilot in primary and secondary care in North East London.

Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials.

New Swedish Biopsy Needle Receives FDA Approval – Secures SEK 17 Million in Capital

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC